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ABSTRACT
BUILDING AN INS-1 cDNA LIBRARY FOR A GENOME-WIDE CRISPR-Cas9
SCREEN.

Idongesit Ekpo
Department of Chemistry and Biochemistry
Bachelor of Science
By the year 2040, an estimated 642 million people are expected to have diabetes
globally. Diabetes results from an elevation of metabolic stressors, such as glucotoxicity,
lipotoxicity, oxidative stress and apoptosis. In type 2 diabetes, these stressful conditions
contribute to the malfunction and loss of functional insulin-producing β-cells. Current
treatment methods for diabetes include insulin therapy, islet transplant and anti-diabetes
medication. These treatments are not curative and ignore other factors that contribute to
the pathogenesis of diabetes beyond insulin resistance and islet β-cell failure. Previous
research on β-cells has focused on ways to replace functional β-cell mass, trigger β-cell
proliferation, protect β-cells from stressors and enhance glucose-stimulated insulin
secretion. While these treatments are effective, they neglect the possibility of unknown
contributing factors. A more effective method is to probe the genetic variation presented
in diabetics so that scientists can understand the disease better and develop curative
methods. One way of doing this is through gene editing using clustered regular
interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9(Cas9).
CRISPR-Cas 9 is a gene-editing tool that modifies DNA using a guide RNA and
an endonuclease called Cas9. The guide RNA directs the Cas9 protein to cut a target
iii

DNA sequence that is complementary to its RNA sequence. This guided mechanism
makes CRISPR-Cas9 the most precise tool for genetic manipulation. Because of its
convenience, CRISPR-Cas9 has been used to create many forward genetic screens. Using
this knowledge of the connection between β-cells and diabetes, and the CRISPR-Cas9
mechanism, we enzymatically generated a CRISPR guide-RNA library of the rat
pancreatic islet β-cell insulinoma (INS-1) cell line. This library can be used to create a
CRISPR-Cas9 knockout (KO) forward genetic screen of all the genes in the INS-1 cell
line required for insulin secretion, β-cell viability, proliferation, and growth. In the future,
this screen will help us identify genes involved in the various mechanistic pathways that
contribute to diabetes. For the library synthesis, we will use the total RNA from INS-1
cells to generate the guide RNA libraries.
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BACKGROUND
An estimated 415 million people worldwide suffer from diabetes, with the vast
majority suffering from type 2 diabetes (T2D).1,2 T2D is characterized by hyperglycaemia
and hyperlipidaemia due to muscle, adipose, and liver tissue insulin resistance.3,4 Insulin
resistance usually has a detrimental effect on β-cell function and viability.5 β-cells are
endocrine cells found in the islet of Langerhans in the pancreas. They are responsible for
producing, storing and secreting insulin.6 Under high blood glucose conditions, β-cells
secrete insulin, but insulin resistance compromises this response.7,8
Insulin resistance throughout the body leads to overworking and exhaustion of βcells resulting in the loss of functional β-cell mass.9,10 Studies indicate that decreased
functional β-cell mass is an early and essential step in T2D disease progression. The βcell dysfunction observed in T2D results in decreased and poorly controlled insulin
secretion and ultimately leads to β-cell death.9 The loss of β-cell function and mass is
driven by various metabolic and stress-related factors including elevated glucotoxicity,
and lipotoxicity.9 Consequently, lipotoxicity and glucotoxicity function as both a cause
and a symptom of T2D, representing a destructive positive feedback loop. Strategies for
replacing functional β-cell mass as a cure for diabetes require some means of protecting
β-cells from continued stress and damage from hyperglycaemia, hyperlipidaemia, and
oxidative stress. Understanding the effects of these stressors and their mechanisms of
action on the β-cells is vital to developing a potential cure for T2D.
To understand the connection between the β-cell transcriptome and diabetes,
Kutlu et al.11 generated a detailed transcriptome of pancreatic β-cells called the Beta Cell
Gene Atlas (BCGA) using massively parallel signature sequencing (MPSS) and
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microarrays. While this inventory has been used to improve β-cell GWAS (genome-wide
associated studies) it has limitations. Some of these limitations include an inability to
identify 7% of genes that lack the DpnII restriction site, generation of false positives and
interference of high G+C content in MPSS.
One method that overcomes the limitations from previous studies is gene editing.
An effective gene-editing tool is the Streptococcus pyogenes clustered regular interspaced
short palindromic repeats (CRISPR)-CRISPR associated protein9 (Cas9) system.
CRISPR-Cas9 is a bacterial adaptive immune response system used to attack invading
pathogens.12,13 It consists of a non-coding RNA called the single guide RNA (sgRNA)
and an endonuclease known as Cas9. The sgRNA directs Cas9 to the target DNA
sequence by locating and binding its complementary DNA sequence. For Cas9 to
function, the target DNA must have an adjacent PAM (protospacer adjacent motif)
site.12,14 The PAM sequence for the S.pyogenes Cas9 is 5'-NGG-3'.15 Unlike other
genome editing tools such as the zinc finger nucleases (ZFN) and the Transcription
activator-like effector nucleases (TALENs), the CRISPR-Cas9 system is precise, easy to
design, and able to modify several genes simultaneously.14 Figure 1 contains a brief
illustration of how the CRISPR-Cas9 system works.
Current improvements in the CRISPR-Cas9 technology has made gene
modification on a genome-wide scale feasible in mammalian cells.16,17 Using a kit that
enzymatically generates CRISPR sgRNA libraries, we created a CRISPR sgRNA library
from the INS-1 832/13 cell-line.18 We hypothesise that it will have around 200,000
distinct sgRNAs targeting about 7000 genes. This will allow us to target and knock out
any gene in the INS-1 genome required for β-cell functionality. To generate this CRISPR
2

sgRNA library, we isolated total RNA from the INS-1 cells and synthesised cDNA from
the RNA. After this, we normalized the cDNA and quantified the normalization. Then
using sgRNA library assembly by ligation on magnetic beads (SLALOM™) technology
for enzymatically generating CRISPR sgRNA libraries, we created an INS-1 guide RNA
library. This INS-1 CRISPR sgRNA library will be used to generate a genome-wide
forward genetic screen of genes directly involved in the T2D pathway. Our study uses the
knowledge of the mechanics of the CRISPR-Cas9 tool to enzymatically generate an INS1 CRISPR sgRNA library. This library will assist with our subsequent plans to study the
influence of genetics on hyperlipidaemia, hyperglycaemia, insulin secretion, and growth
and viability of β-cells.
We aimed to generate an INS-1 CRISPR sgRNA library that can be used to
identify all β-cell genes that play a role in the pathways of different metabolic stressors
and conditions that are characteristic of T2D. With this library, we can look towards
possible curative approaches to treating diabetes.

3

Figure 1. Brief Illustration of The Mechanism of the CRISPR-Cas9 system in INS-1 β-cells. i) A crRNA that is
complementary to the DNA target, and a tracrRNA sequence that associates with the Cas9 protein make up the single
guide RNA (sgRNA). ii) This sgRNA binds the Cas9 protein. iii) The Cas9-sgRNA causes a target-specific doublestranded DNA cleavage. iv)The cleavage site is repaired by nonhomologous end joining (NHEJ). Adapted from
12

Takarabio.com

4

MATERIALS AND METHODS
Experimental Design Overview
This project aimed to generate an INS-1 CRISPR sgRNA library that will use the
CRISPR-Cas9 technology to find β-cell genes involved in the pathways of metabolic
pressures like glucotoxicity, lipotoxicity, oxidative stress, and apoptosis in β-cells. This
project has laid a foundation for future studies involving the identification of these genes
and their specific contributions to these stress pathways.
We cultured INS-1 832/13 cells in complete RPMI 1640 medium. The cell culture
conditions are included in the cell passaging section of this paper. Then we harvested
these cells at a passage number of 52. This low passage number ensures that the
morphology, sensitivity, growth rate, and transfection efficiency of these cells are not
altered.19
Following the cell harvest, we isolated total RNA from these cells and used it to
synthesize cDNA using the two-step reverse transcriptase PCR from Evrogen. Then we
normalized the cDNA to achieve equal distribution of gene transcripts. We quantified this
normalization using qPCR and analysed the results. Finally, we generated a CRISPR
sgRNA library with the normalized cDNA. Figure 2 shows a simple illustration of this
project.

5

Cell Passaging
We cultured INS-1 832/13 cells from a stock solution at a passage number of 50
in RPMI 1640 (+L-glutamine) supplemented with 2 g Sodium Bicarbonate, 10 ml
penicillin/streptomycin, 10 ml 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 10% foetal bovine serum(FBS) and 22 ml Ins-1 supplement.20 These cells were
grown in a T75 flask at 37ºC and in a 5% CO2 incubator. The cells underwent two more
passages before we prepared them for total RNA isolation. At the time of total RNA
isolation, these cells were healthy and at passage number of 52. INS-1 cells are efficient
under 100 passages.
Total RNA Isolation
We harvested the cells by aspirating the culture media and washing them twice
with 5 ml of phosphate buffered saline (PBS). After the PBS washes, we treated the cells
with 2 ml of trypsin for seven minutes. Then, we added 8 ml of PBS to the culture flask.
We aliquoted this cell solution into ten marked Eppendorf tubes each containing 1ml of
the cell solution. We centrifuged these tubes, aspirated the PBS and added 0.5 ml of
Sigma Aldrich TRI Reagent® solution. This cell harvesting protocol is an adaptation of
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the one found on the Tessem Lab Website.21 Using Zymo Research Direct-zol™ RNA
MiniPrep Kit, we isolated total RNA from the INS-1 cells following the manufacturer’s
protocol. Then we confirmed the quality and concentration of isolated RNA using
Thermo Fisher Scientific™ NanoDrop™ One/OneC Microvolume UV-Vis
Spectrophotometer and gel electrophoresis. We determined the purity of the RNA
samples through their 260/280 and 260/230 absorbance ratios. 260/280 and 260/230
ratios of 2.0±0.2 shows that the RNA samples are pure.22 Denaturing agarose gels of total
mammalian RNA shows two bright 28S and 18S rRNA bands.23 We used a nondenaturing agarose gel to check the integrity of our RNA samples and confirmed these
two bands.
cDNA Synthesis
From the isolated total RNA, we synthesized cDNA using the Evrogen Mint-2
cDNA synthesis kit, according to the manufacturer’s protocols. For the first strand
synthesis, we used the 5’-end adapter PlugOligo-1 5’-AAGCAGTGGTATCAACGCAG
AGTACGCGGG-3’ and the 3’-end adapter CDS-1 5’-AAGCAGTGGTATCAACGCAG
AGTAC(T)30VN -3’. We chose these adapters because they lacked the 5’-CCGG-3’
sequence which would interfere with our CRISPR gRNA library generation as this
technology relies on the 5’-CCGG-3’ HpaII site to generate a CRISPR gRNA library.
These adapters also have a poly(T) sequence that is necessary for synthesising cDNA
from mRNA.
For the second strand amplification, we made some modifications to the
conditions suggested in the manufacturer’s protocol as shown in table 2. The average
7

number of cycles that we needed to amplify the second strand cDNA was 24. After the
cDNA synthesis, we purified the cDNA samples with the Zymo Research DNA Clean &
Concentrator™-5 Kit. Then we measured the concentration and quality of the cDNA
using a spectrophotometer. We also ran the cDNA on a 1.5% (w/v) agarose/EtBr gel in
1X TAE buffer. Colour adjustments were made on the gel images using ImageJ and the
gel images were labelled using Microsoft PowerPoint.
cDNA Normalization
Following the generation of the double-stranded(ds) cDNA from total RNA, we
normalized the cDNA using the Evrogen Trimmer-2 cDNA normalization kit. The
normalization step was important because the transcript concentrations of all the genes
must be equalized for this CRISPR sgRNA library to be used to generate a genome-wide
screen that is representative of the INS-1 β-cell transcriptome. High abundance
transcripts (thousands of mRNA copies per cell) that encode about 10 genes usually make
up 20% of the cellular mRNA. Transcripts in medium abundance (hundreds of mRNA
copies per cell) make up 40-60% of the cellular mRNA and the low abundance transcripts
make up the remaining 20-40% of the cellular mRNA.24 Without normalization, we
would get a library that is representative of only genes with high abundance transcripts.
Hence, the normalization process cannot be overlooked. This kit uses a duplex-specific
nuclease-based normalization process described by Zhulidov et al.25,26 to equalize the
transcript concentrations.
The normalization process involves three steps. The first involves denaturing the
ds cDNA at 98ºC and hybridizing it in at 68ºC for 6 hours. The next step involves
treating the hybridized cDNA with different concentrations (1x DSN, ¾x DSN, ½x DSN)
8

of the duplex-specific nuclease (DSN) at 68ºC to find the optimal concentration of DSN
needed for the normalization. For the last step, we amplified the normalized cDNA using
PCR conditions that were modified from the manufacturer’s protocol. These
modifications can be found in table 4. We amplified the normalized cDNA for 22 cycles
in total. The number of cycles must be determined independently for each PCR tube due
to experimental variations. The normalized cDNA was run on a 1.5% (w/v) agarose/EtBr
gel in 1X TAE buffer. Colour adjustments were made on the gel images using ImageJ
and the gel images were labelled using Microsoft PowerPoint.
Measuring normalization using qPCR
To ensure that the cDNA was properly normalized, we ran a quantitative analysis
using quantitative real-time PCR (qPCR). Because the normalization process involves
equalising transcript concentrations in cDNA samples, efficient normalization will show
a relative decrease in the number of high abundance transcripts and a relative increase in
the number of low abundance transcript. For this quantification, it is important to select
genes that have high, intermediate, and low abundance transcripts to measure
normalization effectively. One difficulty that arose here was the absence of trustworthy
data on the transcriptome of INS-1 832/13 cells. We decided to select a few medium to
high-expressing genes based on their functionality in INS-1 β-cells. These genes are
Homeobox protein Nkx-6.1 (Nkx6.1), Insulin, Peptidylprolyl isomerase A (Ppia), Enolase
1 (Eno1), Beta-actin (Actb), Glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and
Succinate dehydrogenase complex, subunit A (Sdha). After selection, we ordered the
primers of these genes from Integrated DNA Technologies. The accession numbers and
sequences of the primers used in this analysis are included in table 1.
9

Table 1. Primer Sequences for Normalization qPCR Analysis

We performed the quantitative analysis using iTaqTM Universal SYBR® Green
Supermix and a Bio-Rad CFX Connect Real-Time PCR Detection System thermal cycler.
For each primer, we conducted triplicate qPCR reactions of the control cDNA(nonnormalized), non-template control (NTC), ¾x, ½x and ¼x DSN treatments. The total
number of reactions for all seven primers was 84. Each reaction consisted of 1µl control
cDNA/ NTC/ ¾x DSN normalized cDNA/ ½x DSN normalized cDNA, 10µl 2× SYBR
Green Master Mix, 2µl forward and reverse primer mix (10µM), and 8µl nuclease-free
water. We ran the reactions under the following PCR conditions, initial denaturation at
95ºC for 3 min, followed by 39 cycles of denaturation at 95ºC for 10 s and annealing at
59ºC for 1 min. At the end of each run, we conducted a melt curve analysis of each PCR
product between 65ºC to 90ºC with 0.5ºC increments.
Analysis of qPCR Data
The cycle threshold (Ct) is the number of qPCR cycles needed for the
fluorescence of a PCR product to pass a certain threshold or to be detected above
background noise.27 Low Ct values mean that a gene is expressed highly because a higher
concentration of cDNA will be amplified earlier in the PCR. The difference between the
average Ct values of the target (normalized cDNA) and the control, ΔCt (ΔCt = CtC –
10

CtN) determines how well the cDNA samples have been normalized. A ΔCt value ≥ 5
shows effective normalization of high-level transcripts. For this analysis, we used an Rscript from the Hill lab to rearrange and generate figures from the qPCR data. This script
is included in the appendices.
Generation of INS-1 CRISPR-Cas9 sgRNA Library
We used the new, affordable and time-efficient technology to generate the INS-1
CRISPR-Cas9 sgRNA library known as SLALOM™ developed in the Hill lab at
Brigham Young University. Unlike other enzymatic methods for generating CRISPR
sgRNA libraries, it is cheap, easy to use, and does not require an inordinate amount of
DNA.28 We followed the manufacturer’s protocol for this sgRNA library synthesis and
ran products on a 1.5% EtBr agarose gel. The manufacturer’s protocol recommended
using a concentration of DNA substrate with at least 10 pmol HpaII cut sites. We
calculated this concentration using the NEBioCalculator® Linear DNA: Mass to Moles
of Ends Converter. The formula from this calculation is included in the appendices.
Colour adjustments were made on the gel images using ImageJ and the gel images were
labelled using Microsoft PowerPoint. The concentration of DNA was measured using a
spectrophotometer.
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RESULTS
cDNA Synthesis Yields High-Quality INS-1 cDNA After Modifications to
Amplification Conditions.
We synthesized INS-1 cDNA from total INS-1 RNA sample 1 (fig. 3) using the
Evrogen Mint-2 cDNA synthesis kit. This RNA sample has a 260/230 ratio of 2.18 and a
260/280 ratio of 1.97. Its concentration was 515.1 ng/ul. Usually, cDNA generated from
total mammalian RNA has a moderate smear and several bright bands that indicate the
presence of abundant transcripts.29 This cDNA synthesis is a two-part protocol. We
generated the single-stranded(ss) cDNA first and then amplified the ss cDNA to get INS1 cDNA. Before the ds cDNA synthesis, we ran an evaluative PCR to determine the
optimal amplification conditions for the INS-1 cDNA. Initially, we followed the
manufacturer’s protocol and did not notice bright cDNA bands when we ran the cDNA
products on a 1.2% EtBr agarose gel (fig. 4a and b).

Figure 3. Total INS-1 RNA Post Isolation.
Total RNA 1 and 2 were isolated from the
same INS-1 cell culture. Total RNA 1 was used
for all experiments downstream of this
i l ti
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After repeating this experiment without noticing significant differences in our
product quality, we decided to modify certain amplification conditions as shown in Table
2. We also decided to increase the concentration of agarose in our gel from 1.2% to 2% to
ensure proper resolution. We ran the PCR of the normal and modified amplification
conditions simultaneously. To verify the quality of the cDNA products and the impact of
our alterations, we ran the cDNA products from our normal PCR on a 2% EtBr agarose
gel and the cDNA products from our modified PCR on a 1.2% EtBr agarose gel. The
amplification took an average of 24 cycles to yield enough ds cDNA. Both amplifications
yielded high-quality cDNA but the cDNA from the modified conditions looked sharper as
shown in figure 4c and d. After determining which conditions were ideal for the INS-1
cDNA amplification, we amplified all the ss cDNA from the previous part of the
experiment and ran them on a 1.5% gel (fig. 4e and f). The gel shows replicates of the
various cDNA samples. We combined these replicates and proceeded to the
normalization. The average yield of ds cDNA for this second strand amplification was
about 350ng/µl.

Normal Conditions
Temp. °C Time
Initial Denaturation
Denaturation
Annealing
Elongation

95
95
66
72

Modified Conditions
Temp. °C Time

1 min
15 s
20 s
3 min

Table 2. Modified INS-1 cDNA Synthesis Amplification Conditions.
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95
95
66
72

45 s
15 s
20 s
2 min

Figure 4. Modifications to Amplification Conditions Yield High-Quality INS-1 cDNA. a) Results of an evaluative
PCR under normal conditions* to determine the optimal number of cycles for cDNA synthesis. This was run on a 1.2% EtBr
agarose gel. Typical electrophoresis of optimally cycled cDNA should show a distinct smear and some bright bands that represent
abundant transcripts. Only three lanes show smears, but no bright bands are visible. b) The products from 3a were cycled three
more times but the results were still disappointing. c) Another evaluative PCR run under normal conditions on a 2% EtBr agarose
gel showed more promising results. Most lanes show a moderately strong smear and several bright bands. d) Evaluative PCR
under modified conditions run on a 1.2% EtBr agarose gel. Modified conditions show brighter bands. The smaller gel to the right
shows the results of cycling samples 1 and 4 two more times. e and f) 1.5%EtBr agarose gel showing replicates of cDNA
synthesized under modified PCR conditions for 24 cycles.

cDNA Normalization and Quantitative Analysis (qPCR)
For the normalization, we used ds cDNA from samples 1, 3 and 4. The first time
we conducted this experiment, we used replicates of the cDNA from sample 1 and
labelled them A, B, and C. Because of the sensitive nature of the DSN enzyme, we had to
conduct an ethanol precipitation of the cDNA after cleaning and concentrating it using
the Zymo™ DNA clean and concentrate kit. The manufacturers of the normalization kit
included an ethanol precipitation protocol. We used a combination of this protocol and
one from The Hla Lab at Harvard University30 to get maximum yield of cDNA post
purification. The manufacturer’s protocol recommends treating each cDNA sample with
different concentrations of DSN. We treated each replicate with 1x, ½x and ¼x amounts
14

of DSN. We also had control cDNA samples that were not treated with DSN. After the
treatment, we amplified the treated and untreated fragments and ran them on a 1.5% gel.
Results of this amplification are shown in figure 5a. Normalized cDNA appears as a
bright smear on agarose gels showing equalized transcript concentrations. After
comparing the results from the normalization amplification, we decided to quantify the
½x and ¼x normalized cDNA from sample A using a qPCR. This quantification showed
that the normalization was inefficient(fig.5b). For genes with high abundance transcripts,
the ΔCt value post-normalization should be ≥5.24 Most of these genes had ΔCt values
below 5 (Table 3).

ΔCt
Gene Name

½x DSN
3.880
3.973
1.063
0.673
-1.730

Eno1
Ppia
Nkx6.1
Insulin
Nr4a2

¼x DSN
3.143
4.713
-0.303
-0.050
-2.323

Table 3. ΔCt Values Showing Failed Normalization.

To ensure that these ΔCt values were not tainted by the quality of our primers, we
analysed the melt curves (not shown) for each primer. We eliminated Nr4a2 primers from
future quantifications because we could not confirm its expression levels in β-cells. We
repeated this normalization with slight changes to the amplification conditions as shown
in table 4. For the repeated normalization, we used cDNA samples 1, 3 and 4 and treated
them with 1x, ¾x and ½x amounts of DSN. Visual comparison of treated samples vs
controls on gel showed samples 4 ¾x and ½x DSN to be most normalized. These samples
were used for the quantification (fig 5c). We also added Gapdh, beta-actin and Sdha
primers to the quantification. This second normalization yielded better results compared
15

to the first. Most of the ΔCt values were above 5 (Table 5). Some of the primers’ melt
curves (not shown) including those of Nkx6.1, Insulin and Eno1 were inconclusive so we
did not use these results to determine the normalization efficiency even though they are
included in the analysis (fig.5d). Overall, we noticed a convergence between pre- and
post-normalized cDNA showing equalized transcript concentrations.
Normal Conditions Modified Conditions
Temp. °C Time
Initial Denaturation
Denaturation
Annealing
Elongation

95
95
66
72

Temp. °C Time
1 min
15 s
20 s
3 min

95
95
65
72

45 s
15 s
20 s
3min 30s

Table 4. Modified INS-1 cDNA Normalization Amplification Conditions.

Figure 5. INS-1 cDNA Normalization Shows Effective Normalization for Some cDNA Samples. a) 1.5% EtBr Agarose gel of
three normalized INS-1 cDNA samples labelled A, B, and C. Each sample is a replicate of the original cDNA. The gel lanes show
each sample treated with 1x, ½x and ¼x amounts of DSN. It also shows the control cDNA of each sample that was not treated
with DSN. An even bright smear signifies efficient normalization. Some of the products showed efficient normalization including
sample A and C’s ½x, and ¼x DSN treated products. b) Quantification of the normalization from a using sample A’s ½x, and ¼x
DSN treated products showed that the normalization was inefficient. c) 1.5% EtBr Agarose gel of normalized INS-1 cDNA
samples labelled A, B, and C. Each sample was treated with 1x, ¾x, and ½x amounts of DSN and the control was untreated as
shown in the gel. Sample C ¾x, and ½x DSN treated products showed the most effective normalization and these samples were
used for the qPCR analysis. d) Quantification of the normalization showed effective normalization.
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ΔCt
Gene Name
Eno1
Ppia
Nkx6.1
Insulin
B-actin
Gapdh
Sdha

3/4 DSN

1/2 DSN

6.650
9.137
Inf
0.553
4.830
9.747
2.767

7.253
8.513
Inf
0.503
5.103
9.410
1.793

Table 5. ΔCt Values Showing Efficient Normalization.

INS-1 CRISPR-Cas9 sgRNA library Shows Promising Results
Using the SLALOM™ method we generated an INS-1 CRISPR-Cas9 sgRNA
library. The results from this library show that the SLALOM™ method works on INS-1
β-cells. We noticed two bands when we ran the sgRNA library on a gel which could be
because one of the ligation steps worked partially (fig.6). Before this library is applied to
other biological processes, we will optimize the library generation protocol for INS-1
cDNA.

Figure 6. INS-1 CRISPR-Cas9 sgRNA library. The
expected size for the INS-1 sgRNA library is 167 bp.
Although the second lane has two strong bands, the top band
17
is where we expect the sgRNA library to appear at 167 bp.

DISCUSSION AND FUTURE DIRECTIONS
Hyperglycaemia and hyperlipidaemia due to muscle, adipose, and liver tissue
insulin resistance are characteristic of T2D.3 This project has brought us one step closer
to understanding the effects of these stressors and their mechanisms of action on β-cells.
The INS-1 CRISPR sgRNA library that we generated can be applied to future work
including creation of a forward genetic CRISPR-Cas9 knockout screen of the INS-1 βcell genome. This screen will help us understand more about the genes involved in the
pre-diabetic stress conditions. Because our library was synthesised using the SLALOM™
method, it can easily be ligated into a lentiviral plasmid which also codes for the Cas 9
protein31 necessary for CRISPR knockdowns in the genome. After the INS-1 β-cells are
transduced with the lentivirus, we will subject them to glucolipotoxic and other stressful
conditions to generate a population of cells that are resistant to these conditions. After
this, we will sequence the genome of these cells and identify genes directly involved in
protecting the cells from these stressors.
Apart from being used to generate a screen of genes that are directly involved in
T2D stress conditions, this library can be applied to other β-cell viability assays. One
such assay is the investigation of the effects of metabolites on β-cell viability. Previous
research has shown that phytochemicals including Fagonia Oliveri, cocoa flavanols and
other flavonoid microbial metabolites enhance glucose-stimulated insulin secretion
(GSIS), boost insulin levels, increase respiration rates, increase the amount of electrontransport chain (ETC) proteins, and alleviate metabolic syndrome.32,33,34 We can treat the
post-transduced INS-1 β-cells with these compounds and subject them to apoptotic and
other stress conditions. These methods will help us discover how these compounds make
18

β-cells resistant to metabolic stressors. This library can also be applied to other cell
viability assays including cell proliferation assays, ATP measurement assays and
apoptotic assays.
Diabetes research has also focused on studying the impact of certain growth and
transcription factors like IGFs, Nkx6.1, Neuro-D and Pdx1 on β-cell growth, identity,
transcription regulation, proliferation, dysfunction, insulin production and insulin
secretion. These studies have shed light on the molecular mechanisms that contribute to
β-cell dysfunction.35,36,37,38This library can be used to discover unknown factors that may
also contribute to the mechanism of β-cell dysfunction. These factors may either act upor downstream of these transcription and growth factors.
In the future, we plan to regenerate this library to achieve a cleaner product. We
will also use this library to carry out a forward genetic CRISPR-Cas9 screen as illustrated
in figure 7. This library will help us discover more about the pathways of pre-diabetic
metabolic stressors. It will also contribute to other diabetes studies including β-cell
viability, transcription factor, and stem cell studies. These studies can then be applied to
developing possible curative approaches to diabetes.
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Figure 7: Future INS-1 CRISPR/Cas9 screen workflow. A stepwise illustration of the conceptual workflow of the
INS-1 CRISPR screen. Adapted from Thomsen and Mikkelsen. 39
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APPENDICES
R-Script For qPCR Data
library(tidyverse)
library(stringi)
# TO DO: Save first page of Quantification Amplification Results file
as "AmplificationData.csv" in working directory (be sure to change file
type from .xlxs to .csv)
quantificationData = read_csv("AmplificationData.csv")
# TO DO: change 97 to number of reactions + 1
quantificationData <- gather(quantificationData, "sample",
"Flouresence",2:97)
# TO DO: Save first page of Quantification Cq Results as "CtData.csv"
in working directory (be sure to change file type from .xlsx to .csv)
CtData = read_csv("CtData.csv")
geneCtData = data.frame(Gene = character(),
Control = double(),
Normalized = double(),
Delta = double())
geneCtData2 = data.frame(Gene = character(),
Control = double(),
Normalized = double(),
Delta = double())
###

TO DO: Repeat for each gene/primer pair ###

# Extracts gene amplification data
# TO DO: Change letter to letter of row for each sample
geneData = filter(quantificationData, grepl("A", sample))
types = c(rep("Untreated Control", 40*3), rep("Normalized Sample DSN
1/2", 40*3), rep("NTC", 40*3), rep("Normalized Sample DSN 1/4", 40*3))
geneData$`Sample Type` = types
# Extracts gene Cq data and calculated Delta Ct value
# TO DO: Change letter to letter of row for each sample
geneCt = filter(CtData, grepl("A", Well))
geneCt$SampleType = c(rep("Control", 3), rep("Normalized", 3),
rep("NTC", 3), rep("Normalized 2", 3))
CtControl = mean(filter(geneCt, SampleType == "Control")$Cq)
CtSample = mean(filter(geneCt, SampleType == "Normalized")$Cq)
CtSample2 = mean(filter(geneCt, SampleType == "Normalized 2")$Cq)
DeltaCt = CtSample - CtControl
DeltaCt2 = CtSample2 - CtControl
# TO DO: Add gene name
geneCtData <- geneCtData %>% add_row(Gene = "[Gene Name]", Control =
CtControl, Normalized = CtSample, Delta = DeltaCt)
geneCtData2 <- geneCtData2 %>% add_row(Gene = "[Gene Name]", Control =
CtControl, Normalized = CtSample2, Delta = DeltaCt2)
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# Plot first Normalized Sample
genePlot <- ggplot(filter(geneData, types != "Normalized Sample DSN
1/4"), aes(x = Cycle, y = Flouresence, line = sample, colour = `Sample
Type`)) +
geom_line() +
theme_bw() +
# TO DO: Add Gene name to graph title
ggtitle("[Gene Name] DSN 1/2") +
geom_vline(xintercept = CtControl, linetype = "dashed", colour =
"blue") +
geom_vline(xintercept = CtSample, linetype = "dashed", colour =
"red") +
theme(plot.title = element_text(hjust = 0.5))
genePlot + annotate("segment", x = CtControl, xend = CtSample, y =
1350, yend = 1350) +
annotate("text", x = CtControl - 3, y = 1375, label = bquote(Delta
~"Ct = " ~ .(DeltaCt)))
# TO DO: Add File name for graph
ggsave("FileName.png")
# Plot second Normalized Sample
genePlot <- ggplot(filter(geneData, types != "Normalized Sample DSN
1/2"), aes(x = Cycle, y = Flouresence, line = sample, colour = `Sample
Type`)) +
geom_line() +
theme_bw() +
# TO DO: Add gene name to title
ggtitle("[Gene Name] DSN 1/4") +
geom_vline(xintercept = CtControl, linetype = "dashed", colour =
"blue") +
geom_vline(xintercept = CtSample2, linetype = "dashed", colour =
"red") +
theme(plot.title = element_text(hjust = 0.5))
genePlot + annotate("segment", x = CtControl, xend = CtSample2, y =
1350, yend = 1350) +
annotate("text", x = CtControl - 3, y = 1375, label = bquote(Delta
~"Ct = " ~ .(DeltaCt2)))
# TO DO: Add file name for graph
ggsave("FileName.png")
## TO DO: repeat previous section for each gene/primer pair ###
# Plot normalization effeciencies
# Ct analysis DSN 1/2
geneCtData <- geneCtData %>% gather("Sample", "Ct", 2:3)
ggplot(geneCtData, aes(x = Sample, y = Ct, colour = Gene, group =
Gene)) +
geom_point() +
geom_line() +
ggtitle("Normalization Effeciency DSN 1/2") +
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scale_y_reverse() +
theme_bw() +
theme(plot.title = element_text(hjust = 0.5)) +
scale_x_discrete(labels = c("Before Normalization", "After
Normalization")) +
xlab("")
# TO DO: Add file name for graoh
ggsave("FileName.png")
# Ct analysis DSN 1/4
geneCtData2 <- geneCtData2 %>% gather("Sample", "Ct", 2:3)
ggplot(geneCtData, aes(x = Sample, y = Ct, colour = Gene, group =
Gene)) +
geom_point() +
geom_line() +
ggtitle("Normalization Effeciency DSN 1/4") +
scale_y_reverse() +
theme_bw() +
theme(plot.title = element_text(hjust = 0.5)) +
scale_x_discrete(labels = c("Before Normalization", "After
Normalization")) +
xlab("")
# TO DO: Add file name for graph
ggsave("FileName.png")
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